質體DNA生產市場：依產品類型、等級、應用、生產類型、開發階段和地區分類的規模、佔有率、前景和機會分析（2025-2032年）

質體DNA生產市場預計在2026年達到16.601億美元，預計到2033年將達到69.511億美元。預計從2026年到2033年，其複合年成長率將達到22.7%。

質體DNA是雙鏈DNA分子，其複製獨立於細菌染色體。質體是存在於細胞內的小型染色體外DNA分子，與染色體DNA物理分離，並能獨立複製。質體最常見於細菌中，呈現小型環狀雙鏈DNA分子形式。然而，古菌和真核生物中也存在質體。

每個質體都有其自身的複製起點。這是一段DNA區域，確保該質粒能夠被宿主細菌複製。因此，質體可以獨立於細菌染色體進行自我複製，在某些情況下，一個細菌細胞內可以存在數百個質體拷貝。

市場動態

為了滿足對合適產品和生產規模的需求，現有製造技術的創新需求日益成長，預計將為市場上的主要參與者帶來巨大的成長機會。例如，2021年3月，位於蓋恩斯維爾的生技公司Evolugate, LLC證明，其專有技術可以提高質體DNA的生產通量。

預計在預測期內，非內部成長策略（例如旨在擴大市場主要參與者產品系列的收購）的增加將推動市場成長。例如，2022年1月，Aldevron宣布收購Nature Technology Corporation (NTC)。 NTC致力於開發用於細胞和基因治療領域的創新專有質體構建體和生產解決方案。 NTC的核酸技術包括Nanoplasmid，這是一種專有的載體構建體，可提高質體和生技藥品的安全性和性能。

本研究的主要特點：

• 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
• 本研究根據以下參數介紹了全球質體DNA製造市場主要公司的概況：公司概況、產品系列、主要亮點、財務表現和策略。研究重點關注的公司包括：Cobra Biologics and Pharmaceutical Services（查爾斯河實驗室）、VGXI, Inc.、Aldevron（丹納赫）、Kaneka Corporation、Nature Technology、PlasmidFactory GmbH & Co. KG、Cell and Gene Therapy Catapult、LakeC, Inc.、McesY, Inc.、McesY、YYia Bio年） LLC、GenScript、GENEWIZ、Creative Biogene、Akron Biotech、Biomay、JAFRAL Ltd.、WuXi Biologics、GeneImmune Biotechnology Corp.、Lonza、Greenpak Biotech Ltd.、Luina Bio（AcuraBio）、Ajinobio Bio-Pharma、Syn Technologies Technologies、Genopis. Inc.、Biomiga、Waisman Biomanufacturing。
• 本報告提供的見解將有助於各公司的行銷負責人和經營團隊就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
• 這份「全球質體DNA製造市場」報告的目標受群眾外包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師等產業相關人員。
• 相關人員可以利用全球質體DNA製造市場分析中使用的各種策略矩陣來促進決策。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
  • 抑制因子
  • 市場吸引力分析
  • 市場機遇
• 產品發布
• 併購和合作
• 監管準則與合規性
• 主要進展
• PEST分析
• 科技趨勢
• 波特的分析
• 價格分析（2022）
• 質體DNA疫苗研發指南
• Genomic Titer

第4章 全球質體DNA生產市場：依產品類型分類，2021-2033年

• 病毒載體
• 質體DNA
• 非病毒

第5章 全球質體DNA生產市場：依等級分類，2021-2033年

• GMP級
• 研發級
• 臨床等級

第6章 全球質體DNA生產市場：依應用領域分類，2021-2033年

• DNA疫苗
• 基因治療
• 免疫療法
• RNA疫苗
• 其他

第7章 全球質體DNA生產市場：依生產類型分類，2021-2033年

• 外包
• 內部生產

第8章 全球質體DNA生產市場：依發展階段分類，2021-2033年

• 臨床前治療
• 處於臨床研發階段的治療藥物
• 市售療法

第9章 全球質體DNA生產市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲國家
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太國家
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 北非
  • 中非
  • 南非

第10章 競爭格局

• Cobra Biologics and Pharmaceutical Services（Charles River Laboratories）.
• VGXI, Inc.
• Aldevron（Danaher）
• Kaneka Corporation
• Nature Technology
• PlasmidFactory GmbH & Co. KG
• Cell and Gene Therapy Catapult
• LakePharma, Inc.
• MeiraGTx Limited
• Eurofins Genomics
• Vigene Biosciences
• Luminous BioSciences（LBS）, LLC
• GenScript
• GENEWIZ
• Creative Biogene
• Akron Biotech
• Biomay
• JAFRAL Ltd.
• WuXi Biologics
• GeneImmune Biotechnology Corp.
• Lonza
• Greenpak Biotech Ltd.
• Luina Bio（AcuraBio）
• Ajinomoto Bio-Pharma
• Synbio Technologies
• Genopis Inc.
• Altogen Biosystems
• Puresyn, Inc.
• Cepham Life Sciences
• Catalent, Inc.
• Biomiga
• Waisman Biomanufacturing

第11章

• 調查方法
• 關於本公司

Plasmid DNA Manufacturing Market is estimated to be valued at USD 1,660.1 Mn in 2026 and is expected to reach USD 6,951.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 22.7% from 2026 to 2033.

Circular double-stranded DNA present in the cytoplasm of a bacteria that replicate independently from the bacterial chromosome is called a plasmid DNA. Plasmids are small extra chromosomal DNA molecules within cells that are physically separated from the chromosomal DNA and capable of independent replication. They are most commonly found as small circular double-stranded DNA molecules in bacteria. However, plasmids can be present in archaea and eukaryotes.

Each plasmid has its own origin of replication. This is a stretch of DNA that ensures it is replicated (copied) by the host bacteria. Because of this, plasmids can copy themselves independently of the bacterial chromosome, and there can be many, possibly hundreds, copies of the plasmid within the bacterial cell.

Market Dynamics

Demand for innovation in existing manufacturing technologies, in order to meet the requirement of appropriate products and its volume is expected to provide immense growth opportunities for key players in the market. For instance, in March 2021, Evolugate, LLC, a Gainesville-based biotech company, has demonstrated that its proprietary technology can be used to improve the throughput of plasmid DNA manufacturing.

The increasing inorganic strategies such as acquisition by the key players in the market to expand product portfolio is expected to drive the market growth over the forecast period. For instance, In January 2022, Aldevron announced the acquisition of Nature Technology Corporation (NTC), a developer of innovative and proprietary plasmid constructs and manufacturing solutions that are used in the field of cell and gene therapy. NTC's nucleic acid-based technologies include Nanoplasmid, a proprietary vector construct that improves the safety and performance of plasmids and biologics.

Key features of the study:

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global plasmid DNA manufacturing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global plasmid DNA manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasmid DNA manufacturing market

Detailed Segmentation:

• Global Plasmid DNA Manufacturing Market, By Product Type (Revenue, USD Mn, 2021 - 2033)
• Viral Vectors
  • Retroviral
  • Adenoviral
  • Lentiviral
  • Adeno Associates
  • Others
• Plasmid DNA
  • mRNA
  • Others
• Non-viral
  • Lipid/Polymer
  • Electroporation
  • Nanoparticles
  • Others
• Global Plasmid DNA Manufacturing Market, By Grade (Revenue, USD Mn, 2021 - 2033)
• GMP Grade
• R&D Grade
• Clinical Grade
• Global Plasmid DNA Manufacturing Market By Application (Revenue, USD Mn, 2021 - 2033)
• DNA Vaccines
• Gene Therapy
• Immunotherapy
• RNA Vaccines
• Others
• Global Plasmid DNA Manufacturing Market By Manufacturing Type (Revenue, USD Mn, 2021 - 2033)
• Outsourcing
• In-house Manufacturing
• Global Plasmid DNA Manufacturing Market By Development Phase (Revenue, USD Mn, 2021 - 2033)
• Pre-Clinical Therapeutics
• Clinical Therapeutics
• Marketed Therapeutics
• Global Plasmid DNA Manufacturing Market, By Region (Revenue, USD Mn, 2021 - 2033)
• North America
  • By Country:
    • U.S.
    • Canada
• Latin America
  • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • By Country:
    • India
    • China
    • Japan
    • Australia
    • ASEAN
    • South Korea
    • Rest of Middle East
• Middle East
  • By Country:
    • GCC
    • Israel
    • Japan
• Africa
  • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
• Cobra Biologics and Pharmaceutical Services (Charles River Laboratories)*
  • Company Highlights
  • Products Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• VGXI, Inc.
• Aldevron (Danaher)
• Kaneka Corporation
• Nature Technology
• PlasmidFactory GmbH & Co. KG
• Cell and Gene Therapy Catapult
• LakePharma, Inc.
• MeiraGTx Limited
• Eurofins Genomics
• Vigene Biosciences
• Luminous BioSciences (LBS), LLC
• GenScript
• GENEWIZ
• Creative Biogene
• Akron Biotech
• Biomay
• JAFRAL Ltd.
• WuXi Biologics
• GeneImmune Biotechnology Corp.
• Lonza
• Greenpak Biotech Ltd.
• Luina Bio (AcuraBio)
• Ajinomoto Bio-Pharma,
• Synbio Technologies, Genopis Inc.
• Altogen Biosystems, Puresyn, Inc.
• Cepham Life Sciences, Catalent, Inc.
• Biomiga
• Waisman Biomanufacturing

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product Type
  • Market Snapshot, By Grade
  • Market Snapshot, By Application
  • Market Snapshot, By Manufacturing Type
  • Market Snapshot, By Development Phase
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Attractiveness Analysis
  • Market Opportunities
• Product Launches
• Merger, Acquisition, Collaborations
• Regulatory Guideline and Compliances
• Key Developments
• PEST Analysis
• Technology Landscape
• PORTER's Analysis
• Pricing Analysis (2022)
• Guidelines Specific for the Development of Plasmid DNA Vaccines
• Genomic Titer

4. Global Plasmid DNA Manufacturing Market, By Product Type, 2021 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Viral Vectors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
    • Retroviral
    • Adenoviral
    • Lentiviral
    • Adeno Associates
    • Others
• Plasmid DNA
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
    • mRNA
    • Others
• Non-viral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
    • Lipid/Polymer
    • Electroporation
    • Nanoparticles
    • Others

5. Global Plasmid DNA Manufacturing Market, By Grade, 2021 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• GMP Grade
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
• R&D Grade
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
• Clinical Grade
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

6. Global Plasmid DNA Manufacturing Market, By Application, 2021 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segments Trends
• DNA Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
• Gene Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
• Immunotherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
• RNA Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

7. Global Plasmid DNA Manufacturing Market, By Manufacturing Type, 2021 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segments Trends
• Outsourcing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
• In-house Manufacturing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

8. Global Plasmid DNA Manufacturing Market, By Development Phase, 2021 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segments Trends
• Pre-Clinical Therapeutics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
• Clinical Therapeutics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
• Marketed Therapeutics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

9. Global Plasmid DNA Manufacturing Market, By Region, 2021 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Grade, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Manufacturing Type, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Grade, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Manufacturing Type, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Grade, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Manufacturing Type, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Grade, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Manufacturing Type, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Grade, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Manufacturing Type, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Grade, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Manufacturing Type, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2021 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Cobra Biologics and Pharmaceutical Services (Charles River Laboratories).*
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• VGXI, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Aldevron (Danaher)
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Kaneka Corporation
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Nature Technology
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• PlasmidFactory GmbH & Co. KG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cell and Gene Therapy Catapult
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• LakePharma, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• MeiraGTx Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Eurofins Genomics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Vigene Biosciences
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Luminous BioSciences (LBS), LLC
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• GenScript
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• GENEWIZ
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Creative Biogene
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Akron Biotech
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Biomay
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• JAFRAL Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• WuXi Biologics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• GeneImmune Biotechnology Corp.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Lonza
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Greenpak Biotech Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Luina Bio (AcuraBio)
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Ajinomoto Bio-Pharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Synbio Technologies
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Genopis Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Altogen Biosystems
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Puresyn, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cepham Life Sciences
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Catalent, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Biomiga
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Waisman Biomanufacturing
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

11. Section

• Research Methodology
• About Us